A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
NCT05425472 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2022-09-06
Summary
To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.
Conditions
- Advanced Esophageal Cancer
Interventions
- DRUG
-
HR070803
HR070803
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-27
- Primary Completion
- 2023-01-30
- Completion
- 2023-03-30
Countries
- China
Study Locations
More Related Trials
-
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
NCT05221658 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
NCT03908671 ·Status: RECRUITING ·Phase: NA
-
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
NCT04215471 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
NCT03817567 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
NCT07128693 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
NCT05637268 ·Status: UNKNOWN ·Phase: PHASE2
-
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05495152 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
NCT04207918 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib Treatment for Advanced Esophagus Cancer
NCT03170310 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
NCT03187314 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT04540211 ·Status: COMPLETED ·Phase: PHASE3
-
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
NCT05349045 ·Status: UNKNOWN
-
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
NCT04415853 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05476380 ·Status: UNKNOWN ·Phase: PHASE2
-
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
NCT05022654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SOX-based CRT for Esophageal Cancer.
NCT03991104 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
NCT03933449 ·Status: COMPLETED ·Phase: PHASE3
-
Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
NCT00950417 ·Status: COMPLETED ·Phase: PHASE1
-
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
NCT02591784 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
NCT02645864 ·Status: COMPLETED ·Phase: PHASE1
-
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
NCT07312578 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy
NCT04508829 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
NCT03542422 ·Status: UNKNOWN ·Phase: PHASE2